ImaBiotech Expands Bioanalytical Pharmaceutical Services in North America with Pyxant Labs Colorado and Salt Lake City Sites
ImaBiotech Group today announced the creation of an innovative global bioanalytical CRO with Pyxant Labs Inc Colorado Springs and Salt Lake City sites The integration of the expertise, innovation and analytical platforms of the companies to form a leading global bioanalytical services provider will provide a unique offering to pharmaceutical and cosmetic companies.
Encompassing unique proprietary drug and biomarker imaging (Mass Spectrometry Imaging), multi omics, spatialomics capabilities and well established high performance bioanalytical GLP services, the combined platforms will offer access to a unique set of services spanning the drug development cycle, from early stage discovery through Phase IV These services reduce the rate of failure and accelerate the development of safer therapies In conjunction to the operation, the company received a majority investment from ArchiMed SAS a leading private equity fund focused on the healthcare sector.
This deal enables a continuing commitment to further extend these specialized capabilities, creating a major player focused exclusively on bioanalytical excellence where the deep science paradigm, a relentless focus on customer service, and innovative proprietary technology will enable and accelerate therapeutic innovation for our clients.
“I am very pleased to expand our activities in North America and Europe with Pyxant Labs and Archimed said former founder and CEO of ImaBiotech Jonathan Stauber, PhD Archimed brings exceptional healthcare expertise with insight into advanced bioanalytical services, and the combination of Pyxant Labs’ established bioanalytical capabilities with ImaBiotech’s innovative imaging technologies will provide a unique service offering to our customers in the US, Europe and Asia, representing a tremendous opportunity to grow in the CRO market.”
“ImaBiotech’s deep science paradigm and focus on customer service were two essential characteristics in common with our business paradigms, which motivated us toward this combination,” commented Maurice Gaubatz CEO of Pyxant Labs ..”Joining forces with Jonathan’s organization bridges ImaBiotech’s unique mass spectrometry imaging capabilities with Pyxant Labs’ regulatory development bioanalytical services and provides coverage from early research through Phase IV development The combined enterprise creates an international footprint and leading standing among CROs exclusively focused on mass spectrometry bioanalytical excellence.”
The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2021